PHARMA NORD ApS: Financial statements 2020
CVR: 67303016
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2020. In 2020, the company reported revenue of DKK 417,178,000 and a net result of DKK 51,949,000 compared with DKK 41,501,000 the year before. That is an increase of 25.3% compared with the year before. The profit margin was 12.5%. Equity in the 2020 report amounted to DKK 170,425,000. The solvency ratio was 41.1%. The company had 394 employees in the financial year.
- Revenue
- DKK 417,178,000
- Gross Profit
- DKK 197,883,000
- Profit/Loss
- DKK 51,949,000
- Equity
- DKK 170,425,000
- Total Assets
- DKK 415,020,000
- Employees
- 394
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | 417.2 mio. | 197.9 mio. | 51.9 mio. | 170.4 mio. | 394 |
| 2019 | 333 mio. | 126.1 mio. | 41.5 mio. | 269.7 mio. | 375 |
| 2018 | 334 mio. | 132.3 mio. | 37.7 mio. | 212.7 mio. | 364 |
| 2017 | 343.1 mio. | 135.4 mio. | 46.8 mio. | 181.9 mio. | 378 |
| 2016 | 337.3 mio. | 149.4 mio. | 62 mio. | 142 mio. | 315 |
Official annual report
How creditworthy is PHARMA NORD ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of December 14, 2020, Sven Moesgaard has stepped down as director of PHARMA NORD ApS.
PHARMA NORD ApS has published its annual report for 2019. Revenue came to DKK 332,992,000, and the net result was DKK 41,501,000.
As of May 29, 2020, Eli Wallin is registered as adm. dir. of PHARMA NORD ApS.
As of May 28, 2020, Eli Wallin has stepped down as director of PHARMA NORD ApS.
As of January 28, 2020, PharmCo III ApS is registered as an owner of PHARMA NORD ApS with an ownership share of 33%.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.